BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B
63.425
USD
1.09
(1.75%)
Post Trading·63.490USD+0.065(+0.10%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 12.66B
OverviewFinancialsNewsForecastEarningsDividendsCompany

Bristol-Myers Squibb revenue 1987–2026

Bristol-Myers Squibb's revenue in Q3 FY2026, the three months to 30 September 2026, was 13.07B USD, up 6.9% on the same quarter a year before. Bristol-Myers Squibb's revenue over the last twelve months was 50.03B USD, up 4.2% on the twelve months before. In fiscal year 2025 it was 48.20B USD, down 0.2% on the year before.

Last updated 12 Nov 2026 · Next report 4 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202650.03B+4.16%34.64B9.24B
FY202531 Dec 202548.20B-0.22%34.26B7.05B
FY202431 Dec 202448.30B+7.32%34.33B-8.95B
FY202331 Dec 202345.01B-2.50%34.31B8.03B
FY202231 Dec 202246.16B-0.49%36.02B6.33B
FY202131 Dec 202146.39B+9.09%36.45B6.99B
FY202031 Dec 202042.52B+62.62%30.75B-9.02B
FY201931 Dec 201926.15B+15.89%18.07B3.44B
FY201831 Dec 201822.56B+8.59%16.09B4.92B
FY201731 Dec 201720.78B+6.94%14.76B1.01B
FY201631 Dec 201619.43B+17.31%14.46B4.46B
FY201531 Dec 201516.56B+4.29%12.65B1.57B
FY201431 Dec 201415.88B-3.09%11.95B2.00B
FY201331 Dec 201316.39B-7.01%11.77B2.56B
FY201231 Dec 201217.62B-17.05%13.01B1.96B
FY201131 Dec 201121.24B+9.03%15.65B3.71B
FY201031 Dec 201019.48B+3.59%14.21B3.10B
FY200931 Dec 200918.81B-8.69%13.67B10.61B
FY200831 Dec 200820.60B+6.46%12.40B5.25B
FY200731 Dec 200719.35B+8.00%13.13B2.17B
FY200631 Dec 200617.91B-6.73%11.52B1.59B
FY200531 Dec 200519.21B-0.89%12.87B3.00B
FY200431 Dec 200419.38B-7.25%13.39B2.39B
FY200331 Dec 200320.89B+15.32%13.25B3.11B
FY200231 Dec 200218.12B-6.71%11.57B2.14B
FY200131 Dec 200119.42B+6.63%12.53B4.83B
FY200031 Dec 200018.22B-9.92%13.46B4.71B
FY199931 Dec 199920.22B+10.60%13.01B4.17B
FY199831 Dec 199818.28B+9.48%11.79B3.14B
FY199731 Dec 199716.70B+10.86%12.83B3.21B
FY199631 Dec 199615.07B+9.43%11.62B2.85B
FY199531 Dec 199513.77B+14.88%10.58B1.81B
FY199431 Dec 199411.98B+5.00%9.19B1.84B
FY199331 Dec 199311.41B+2.30%8.69B1.96B
FY199231 Dec 199211.16B-0.03%8.59B1.96B
FY199131 Dec 199111.16B+8.34%8.48B2.06B
FY199031 Dec 199010.30B+12.09%7.67B1.75B
FY198931 Dec 19899.19B+7.37%6.73B747.00M
FY198831 Dec 19888.56B+13.23%6.26B1.25B
FY198731 Dec 19877.56B—5.42B1.07B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Bristol-Myers Squibb revenue growth by segment

Q3 FY2026 against Q3 FY2025

Eliquis4.69B
+25.2%
Opdivo2.37B
-6.2%
Orencia983.00M
+2.0%
Yervoy793.00M
+7.3%
Reblozyl750.00M
+22.0%
Other Growth Brands731.00M
+42.2%
Breyanzi526.00M
+46.5%
Camzyos420.00M
+41.9%
Opdualag367.00M
+22.7%
Opdivo Ovantig334.00M
+398.5%
Revlimid303.00M
-47.3%
Zeposia168.00M
+4.3%
Other Legacy Brands154.00M
-13.0%
Pomalyst/Imnovid130.00M
-80.7%
Sotyktu100.00M
+25.0%
Sprycel73.00M
-38.7%
Abraxane65.00M
-12.2%
Krazati58.00M
+9.4%
Cobenfy57.00M
+32.6%

Bristol-Myers Squibb revenue by segment over time

Eliquis Opdivo Orencia Revlimid Yervoy Pomalyst/Imnovid Reblozyl Other Growth Brands Breyanzi Opdualag Camzyos Other Legacy Brands Zeposia Sprycel Abecma Abraxane Sotyktu Opdivo Ovantig Krazati Cobenfy Abilify Reyataz Baraclude Empliciti Sustiva Franchise Hepatitis C Portfolio Mature Products And All Other
Fiscal yearEliquisOpdivoOrenciaRevlimidYervoyPomalyst/ImnovidReblozylOther Growth BrandsBreyanziOpdualagCamzyosOther Legacy BrandsZeposiaSprycelAbecmaAbraxaneSotyktuOpdivo OvantigKrazatiCobenfyAbilifyReyatazBaracludeEmplicitiSustiva FranchiseHepatitis C PortfolioMature Products And All Other
FY202514.44B +8.3%10.05B +8.0%3.71B +0.6%2.95B -48.9%2.90B +14.6%2.73B -22.9%2.33B +31.2%1.92B +19.9%1.36B +81.8%1.19B +27.7%1.07B +77.4%798.00M -13.7%577.00M +1.9%493.00M -61.7%427.00M +5.2%368.00M -57.9%291.00M +18.3%238.00M 205.00M +62.7%155.00M +1,450.0%— — — — — — —
FY202413.33B +9.2%9.30B +3.3%3.68B +2.2%5.77B -5.3%2.53B +13.0%3.55B +3.0%1.77B +75.9%1.61B 747.00M +105.2%928.00M +48.0%602.00M +160.6%925.00M 566.00M +30.4%1.29B -33.4%406.00M -14.0%875.00M -12.8%246.00M +44.7%— 126.00M 10.00M — — — — — — —
FY202312.21B +3.5%9.01B +9.2%3.60B +4.0%6.10B -38.9%2.24B +5.0%3.44B -1.6%1.01B +40.6%— 364.00M +100.0%627.00M +148.8%231.00M +862.5%— 434.00M +73.6%1.93B -10.9%472.00M +21.6%1.00B +23.8%170.00M +2,025.0%— — — — — — — — — —
FY202211.79B +9.5%8.25B +9.7%3.46B +4.8%9.98B -22.2%2.13B +5.2%3.50B +5.0%717.00M +30.1%— 182.00M +109.2%252.00M 24.00M — 250.00M +86.6%2.17B +2.3%388.00M +136.6%811.00M -31.3%8.00M — — — — — — — — — 1.75B -7.9%
FY202110.76B +17.4%7.52B +7.6%3.31B +4.7%12.82B +5.9%2.03B +20.5%3.33B +8.5%551.00M +101.1%— 87.00M — — — 134.00M +1,016.7%2.12B -1.1%164.00M 1.18B -5.3%— — — — — — — — — — 1.90B +44.5%
FY20209.17B +15.6%6.99B -2.9%3.16B +6.0%12.11B +831.9%1.68B +13.0%3.07B +853.4%274.00M — — — — — 12.00M 2.14B +1.4%— 1.25B +651.2%— — — — — — 447.00M -19.5%381.00M +6.7%— — 1.32B -21.4%
FY20197.93B +23.2%7.20B +7.0%2.98B +9.9%1.30B 1.49B +12.0%322.00M — — — — — — — 2.11B +5.5%— 166.00M — — — — — — 555.00M -25.4%357.00M +44.5%— — 1.67B +2.7%
FY20186.44B +32.1%6.74B +36.1%2.71B +9.3%— 1.33B +6.9%— — — — — — — — 2.00B -0.2%— — — — — — — 427.00M -38.8%744.00M -29.3%247.00M +6.9%283.00M -61.2%17.00M -95.8%1.63B -22.8%
FY20174.87B +45.7%4.95B +31.1%2.48B +9.4%— 1.24B +18.1%— — — — — — — — 2.01B +9.9%— — — — — — — 698.00M -23.5%1.05B -11.7%231.00M +54.0%729.00M -31.5%406.00M -74.3%2.11B -1.4%
FY20163.34B +79.7%3.77B +300.6%2.27B +20.2%— 1.05B -6.5%— — — — — — — — 1.82B +12.6%— — — — — — 128.00M -82.8%912.00M -19.9%1.19B -9.1%150.00M +4,900.0%1.07B -14.9%1.58B -1.6%2.14B -16.6%

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Bristol-Myers Squibb's revenue

Source: Financial Modeling PrepVerified against SEC filings